RU2489155C2 - Лечение нейродегенеративных заболеваний - Google Patents

Лечение нейродегенеративных заболеваний Download PDF

Info

Publication number
RU2489155C2
RU2489155C2 RU2008142514/15A RU2008142514A RU2489155C2 RU 2489155 C2 RU2489155 C2 RU 2489155C2 RU 2008142514/15 A RU2008142514/15 A RU 2008142514/15A RU 2008142514 A RU2008142514 A RU 2008142514A RU 2489155 C2 RU2489155 C2 RU 2489155C2
Authority
RU
Russia
Prior art keywords
selenate
disease
pharmaceutically acceptable
acceptable salt
dementia
Prior art date
Application number
RU2008142514/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008142514A (ru
Inventor
Кристофер ХОВЕНС
Ниалл КОРКОРАН
Original Assignee
Велакор Терапеутикс Пти Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Велакор Терапеутикс Пти Лтд filed Critical Велакор Терапеутикс Пти Лтд
Publication of RU2008142514A publication Critical patent/RU2008142514A/ru
Application granted granted Critical
Publication of RU2489155C2 publication Critical patent/RU2489155C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2008142514/15A 2006-03-29 2007-03-29 Лечение нейродегенеративных заболеваний RU2489155C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
USUS60/787,240 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
RU2008142514A RU2008142514A (ru) 2010-05-10
RU2489155C2 true RU2489155C2 (ru) 2013-08-10

Family

ID=38540722

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008142514/15A RU2489155C2 (ru) 2006-03-29 2007-03-29 Лечение нейродегенеративных заболеваний

Country Status (14)

Country Link
US (2) US8920851B2 (enExample)
EP (1) EP2004204B1 (enExample)
JP (1) JP5542430B2 (enExample)
KR (1) KR101451439B1 (enExample)
CN (1) CN101478977B (enExample)
AU (1) AU2007231547B2 (enExample)
BR (1) BRPI0709033A2 (enExample)
CA (1) CA2644441C (enExample)
DK (1) DK2004204T3 (enExample)
ES (1) ES2394348T3 (enExample)
MX (1) MX2008012479A (enExample)
NZ (2) NZ571835A (enExample)
RU (1) RU2489155C2 (enExample)
WO (1) WO2007109851A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067008B2 (en) 2004-08-23 2011-11-29 Yeda Research And Development Co. Peptide inhibitors for mediating stress responses
DK2004204T3 (da) 2006-03-29 2013-01-07 Velacor Therapeutics Pty Ltd Behandling af neurodegenerative sygdomme med selenat
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
JP2011504474A (ja) * 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
EP2485722A1 (en) * 2009-10-09 2012-08-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
WO2012160563A2 (en) 2011-05-23 2012-11-29 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016150403A1 (en) * 2015-03-26 2016-09-29 Fujian Tiantai Medical Technology Co. Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
IL309939A (en) * 2018-06-29 2024-03-01 Rejuvenate Biomed Pharmaceutical combination for use in age-related and/or degenerative diseases
AU2020247907B2 (en) 2019-03-26 2025-12-11 Seer, Inc. Compositions, methods and systems for protein corona analysis from biofluids and uses thereof
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPH04247033A (ja) * 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
CA2523714A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CN101073584B (zh) * 2005-10-14 2012-10-10 全面技术公司 改变细胞功能的方法和组合物
CA2644445A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors
DK2004204T3 (da) 2006-03-29 2013-01-07 Velacor Therapeutics Pty Ltd Behandling af neurodegenerative sygdomme med selenat

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAFAR KS et al. Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Neurochem. 2003 Feb; 84(3):438-46, он-лайн, [найдено 06.10.2011] найдено из Интернет, http://www.ncbi.nlm.nih.gov/pubmed/12558963. BRENNEISEN H et al. "Selenium, oxidative stress, and health aspects". Mol Aspects Med 2005 Aug-Oct; 26(4-5):256-67, реферат [найдено 19.01.2011], найдено из PubMed PMID: 16105679. *

Also Published As

Publication number Publication date
DK2004204T3 (da) 2013-01-07
EP2004204B1 (en) 2012-09-12
JP2009532340A (ja) 2009-09-10
CA2644441C (en) 2014-09-09
RU2008142514A (ru) 2010-05-10
KR20090015038A (ko) 2009-02-11
MX2008012479A (es) 2009-08-13
CN101478977A (zh) 2009-07-08
AU2007231547B2 (en) 2012-07-12
CN101478977B (zh) 2013-03-27
NZ571835A (en) 2011-11-25
EP2004204A1 (en) 2008-12-24
AU2007231547A1 (en) 2007-10-04
WO2007109851A1 (en) 2007-10-04
US20090169649A1 (en) 2009-07-02
NZ596244A (en) 2013-05-31
US20140141104A1 (en) 2014-05-22
US8920851B2 (en) 2014-12-30
KR101451439B1 (ko) 2014-10-16
BRPI0709033A2 (pt) 2011-06-21
ES2394348T3 (es) 2013-01-30
CA2644441A1 (en) 2007-10-04
EP2004204A4 (en) 2010-06-02
JP5542430B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
RU2489155C2 (ru) Лечение нейродегенеративных заболеваний
JP2009532340A5 (enExample)
Dezsi et al. Monoamine oxidase B inhibitors in Parkinson's disease
JP6766198B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
JP2011522035A5 (enExample)
CN102065897B (zh) 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
CN102105169B (zh) 用于治疗帕金森病的药物组合物
JP2016210798A5 (enExample)
JP2025521818A (ja) ブプロピオンとデキストロメトルファンの併用によるデキストロメトルファン低代謝群の治療
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
JP2020503323A5 (enExample)
CN101657193A (zh) 用于治疗纤维肌痛的屈昔多巴及其药物组合物
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
HUE034615T2 (en) New therapeutic approaches for treating parkinson's disease
US20180311236A1 (en) Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
TW200738228A (en) Neramexane modified release matrix tablet
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
JP2018500300A (ja) パーキンソン病を遅延させるための医薬
CN107949379A (zh) L‑4‑氯代犬尿氨酸的治疗用途
Lewis et al. A pharmacokinetic study of an ibuprofen topical patch in healthy male and female adult volunteers
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
JP2016505050A5 (enExample)
Aisen Anti‐inflammatory therapy for Alzheimer's disease: implications of the prednisone trial
Peskind Pharmacologic approaches to cognitive deficits in Alzheimer's disease
JP2019504872A5 (enExample)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160330